Form 4: Regeneron EVP Joseph LaRosa Reports Stock Transactions

Joseph LaRosa, EVP, General Counsel, and Secretary of Regeneron Pharmaceuticals, reports the disposition of 702 shares of common stock to cover tax obligations.

Summary

• On December 16, 2024, Joseph LaRosa, EVP, General Counsel, and Secretary of Regeneron Pharmaceuticals, disposed of 702 shares of common stock to cover tax obligations.
• The transaction was executed at a price of $730.81 per share.
• Following the transaction, LaRosa directly owns 30,075 shares of Regeneron common stock.
• LaRosa also indirectly owns 9,000 shares through a 2024 GRAT and 371 shares through a 401(k) plan.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing a stock transaction. It doesn't inherently convey positive or negative sentiment, as it's a factual report of an insider's trading activity.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when corporate insiders engage in transactions involving their company's stock. It provides transparency to the market regarding the actions of key executives.

Stakeholder Impact

• The transaction has a minimal impact on shareholders, as it's a relatively small sale by an executive.
• The sale is related to tax obligations, which is a normal part of executive compensation.

Key Dates